Sean Brynjelsen - 07 Feb 2022 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
President & CEO, Director
Signature
/s/ W. Wilson Troutman
Issuer symbol
ETON
Transactions as of
07 Feb 2022
Net transactions value
$0
Form type
4
Filing time
28 Feb 2022, 15:27:19 UTC
Previous filing
20 Aug 2021
Next filing
18 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Stock Option(Right to buy) Award $0 +416,500 +35% $0.000000 1,601,500 07 Feb 2022 Common Stock 416,500 $3.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in 24 equal monthly installments from the date of grant until fully vested and exercisable on February 7, 2024.